drugset / Trial / NCT00003253

Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer

NCT00003253 ↗

Phase 2 Unknown 100 enrolled Oncotech
Diagnostic

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Some patients may develop a resistance to chemotherapy drugs. PURPOSE: Phase II trial to determine the reliability of a test for measuring drug resistance to paclitaxel in patients with metastatic breast cancer.

Timeline

Start
1997-07
Primary completion
—
Completion
—

Publications

  • Results Fruehauf JP, Mehta RS, Parker RJ: Association of invitro resistance to paclitaxel with clinical outcome in metastatic breast cancer patients with taxol: a multi-institutional prospective trial. [Abstract] Proc Am Assoc Cancer Res 41: A-2096, 330, 2000.

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule — Intravenous

Indications